Newsroom
BioLamina and IndiCell project partners start developing individualized stem cell therapy workflows in Sweden
The aspiring project is funded for 5-years by the Swedish Agency for Innovation and is led by Lund University. The project will first focus on treatments for Parkinson’s Disease and Macular Degeneration. The long-term vision for the innovation milieu is to become a major center for supporting induced pluripotent stem cell-based treatments of various diseases in Sweden.
19th October 2021
-
BioLamina with partners in the innovation milieu IndiCell receive SEK 40M to establish and propel individualized cell therapy treatments in Sweden
-
Appointment of new CEO at BioLamina AB
-
BioLamina AB expands production and office space to meet the fast-growing customer demand
-
BioLamina AB and Inventia Life Science partner to advance cell matrices for complex 3D cell models
-
BioLamina AB launches new website
-
BioLamina AB and partners granted € 6.1M in funding to develop organ-on-chip system for animal-free modelling of human diseases
-
BioLamina and Cellaria will collaborate to make accurate cell models for drug screening
-
Biolamina and Spiber Technologies sign exclusive sales and marketing deal for unique Biosilk products
-
Stay updated on the latest publications and offers by signing up to the BioLamina Newsletter
-
BioLamina and Novo Nordisk partner to advance stem cell based therapies for three common medical conditions
-
BioLamina and partners aim to develop new methods to differentiate unlimited amounts of NK-cells to fight cancer
-
BioLamina announces an OEM partnership with Cellink for the development of biologically relevant bioink products for bioprinting
-
Webcast series: Rising stars
-
Customer testimonials
-
Founder of BioLamina: Karl Tryggvason
-
Stem cell innovator: Abdenour Soufi